Position in AZN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$243,362,577
New position
Shares Held
1,233,965
first reported quarter
Ownership
0.080%
of shares outstanding
% of Portfolio
0.45%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 0.ToString("F0")%
Shared 100.ToString("F0")%
None 0.ToString("F0")%
Derivatives in AZN
reported options exposure · as of Mar 31, 2026CallValue
$2,179,281
CallShares
11,050
PutValue
$4,033,149
PutShares
20,450
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - General
Healthcare · as of Mar 31, 2026Point72 Asset Management, L.P. holds $795,359,411 across 11 Drug Manufacturers - General names. AZN ranks #1 (30.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AZN |
Astrazeneca PLC
This page
|
1,233,965 | $243,362,577 | |
| 2 | BIIB |
Biogen Inc.
|
809,617 | $148,427,084 | |
| 3 | PFE |
Pfizer Inc
|
4,365,063 | $122,570,969 | |
| 4 | MRK |
Merck & Co., Inc.
|
921,077 | $110,796,352 | |
| 5 | LLY |
ELI LILLY & Co
|
95,766 | $88,082,693 | |
| 6 | NVS |
Novartis AG
|
283,837 | $43,356,101 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
531,198 | $32,217,158 | |
| 8 | AMRN |
Amarin Corp Plc\Uk
|
240,761 | $3,481,404 |
All Filings in AZN
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $4,033,149 | 20,450 | Put | Defined | 2026-05-15 | |
| 2026-03-31 | $2,179,281 | 11,050 | Call | Defined | 2026-05-15 | |
| 2026-03-31 | $243,362,577 | 1,233,965 | Shares | Defined | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||